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Renal vascular disease in the elderly. The aging of Western
societies is causing a progressive increase in the number of
patients over 65 starting dialysis. The EDTA Registry shows that
in 1995 this section of the population represented nearly 45% of
patients under dialysis, and the percentage is even higher in the
USRDS at 48%, 20% of whom are over 75. These changes have
not only been quantitative, but have also modified the causes of
end-stage renal disease (ESRD). Diabetic nephropathy (DN) and
renal vascular disease (RVD) account for more than 50% of all
these causes, reaching 66% according to the latest USRDS
calculations. According to these numbers, RVD represents 29%
of all causes, the incidence varying with the age group, and has
become the main cause of ESRD in the elderly (38% of all cases).
Until a few years ago, RVD was synonymous with hypertension,
but as the population ages, the range of diseases in this group is
increasing. The main RVDs that cause ESRD in the elderly are:
hypertensive RVD (nephrosclerosis), atheromatous RVD (either
as ischemic atherosclerotic nephropathy or as atheroembolism),
and acute occlusion of renal arteries (either bilateral or unilateral
in single-kidney patients). The diagnosis of nephrosclerosis in the
absence of histological confirmation is a presumed clinical diag-
nosis, made in most cases by exclusion, and is therefore clearly
overestimated. On the other hand, atheromatous RVD is an
underdiagnosed disease that is often overlooked. The prevalence,
natural history, diagnosis and prognosis are discussed in this
report.
The aging of Western societies has caused a progressive
increase in the number patients over 65 starting dialysis.
Data from the EDTA Registry show that this section of the
population has grown from 9% in 1977 to 38% in 1992,
12% of whom were over 75 [1]. This trend has continued,
and today this age group represents 45% of all patients on
renal replacement therapy. The same phenomenon has
been reflected in other registries. In the latest report of the
USRDS, referring to 1995 data, 48% of patients starting
dialysis were over 65 and 20% were over 75 [2].
These changes have not only been quantitative, but have
also modified the causes of end-stage renal disease
(ESRD), so that diabetic nephropathy (DN) and renal
vascular disease (RVD) currently account for more than
50% of these causes, 66% in the latest figures from the
USRDS. According to this source, RVD represents 29% of
ESRD patients in all age groups, and although the inci-
dence varies in different age groups (at least in the USA),
RVD has become the main cause of ESRD in the elderly,
with an incidence of 38% [2].
Until a few years ago, RVD was synonymous with
hypertension, but due to the growing number of elderly
patients the range of diseases that make up this group is
widening. Today we can consider the following RVDs as
causes of ESRD in the elderly: inflammatory vasculitis,
nephrosclerosis, RVD atheromatous and embolic disease.
We will not discuss vasculitis because, although it is fre-
quently found in the elderly and still responsible for 1 to
2% of all cases of ESRD, is still included in all registries
within the group of multiorganic or systemic diseases. We
shall also exclude acute occlusion of the renal artery, a less
common cause of ESRD that is responsible for 1% of all
cases, since it has a clear antecedent and characteristic
clinical manifestations.
The focus of this study will be on those causes that are
the most prevalent (hypertensive RVD and atheromatous
RVD), since the former is an overestimated and the latter
is an underdiagnosed (if not unsuspected) disease.
HYPERTENSIVE VASCULAR DISEASE
(NEPHROANGIOSCLEROSIS)
Nephroangiosclerosis, or nephrosclerosis, is a histologi-
cal concept used since the first decades of this century to
define the microscopic changes of the preglomerular mi-
crovasculature seen in hypertensive patients.
However, renal biopsy is rarely performed in practice on
a patient with hypertension and renal failure, especially if
the patient is elderly. The diagnosis of nephrosclerosis in
the absence of histological confirmation is therefore a
suspected clinical diagnosis, in most cases made by exclu-
sion in a patient with progressive renal failure and renal
atrophy in the absence of marked proteinuria, or in a
patient with long-standing hypertension and organ involve-
ment who has no evidence of pyelonephritis, glomerulone-
phritis (GN) or metabolic disease (Table 1).
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This diagnosis may therefore be somewhat vague, mak-
ing it an overestimated cause of ESRD.
Innes et al reviewed the Medical Research Council
(MRC) Glomerulonephritis Registry, a multicenter study
including 7339 renal biopsies from patients who were
defined as having benign nephrosclerosis by clinical criteria
[3]. Of these patients, 185 (2.5%) were then classified as
having benign nephrosclerosis. Proteinuria was . 1.5 g/day
in 40% and . 3 g/day in 22%, with hypoalbuminemia in
18%. These proteinuria findings within the nephrotic range
further complicate the diagnosis of nephrosclerosis based
only on clinical criteria.
Harvey et al reported a series of 27 patients diagnosed by
clinical criteria as having nephrosclerosis, and found that 6
of them (22.5%) showed well individualized GN (3 IgA
GN, 2 NM and 1 GNMP) [4]. Schlessinger, Tankersley and
Curtis reviewed the clinical histories of 43 patients referred
to the University of Alabama for renal transplant with the
unequivocal nephrological diagnosis of nephrosclerosis and
noted that in the renal biopsy of six of them (14%), the
findings were different from those typical of benign nephro-
sclerosis [5]. Normal renal function at detection of hyper-
tension was documented in less than 5% of cases, and more
than 20% showed proteinuria . 1.5 g/day. They concluded
that, in order to establish the diagnosis of nephrosclerosis,
renal dysfunction at the time of first recording hypertension
should be discarded. Otherwise, it may be better to classify
the ESRD as from a non-related etiology. However, with
stricter diagnostic criteria, such as those used by the
African American Study of Kidney Disease (AASK) [6], a
diagnostic sensitivity of 97% may be achieved.
Natural history
The incidence of renal failure in essential hypertension is
a controversial subject that has been recently reviewed
[7–9]. Until a few years ago, neither large observational
studies nor intervention studies included renal function
parameters, and therefore there are no long-term prospec-
tive studies available for analysis. When the results of
ongoing studies are published the subject may be clarified
[10]. At any rate, the incidence seems to be low, and the
results of the Hypertension Detection and Follow-Up
Program (HDFP), which studied a group of 10,940 pa-
tients, show an increase by at least 25% in previous serum
creatinine levels in 2% of the treated patients over a period
of five years.
Proper control of hypertension seems to prevent, or at
least delay, the progression of renal failure [11]. This can be
deduced from observational studies and active treatment/
placebo studies on more than 2,000 patients. Taking as the
end point the doubling of urea/creatinine values, the per-
centage of patients treated with a placebo that reached that
point ranged from 1 to 1.5% during a follow-up period of
three to seven years. In patients on active treatment, the
rate ranged from 0.12 to 0.17% during a seven-year period
[12].
From these data, we can deduce that a relatively small
proportion of patients with slight to moderate hypertension
show an impairment in renal function depending on
whether or not they receive treatment. The differences
observed in the different studies appear to be due to race,
age and objectives [13].
VASCULAR ATHEROMATOUS DISEASE
This may occur as ischemic nephropathy secondary to
atherosclerotic stenosis of the renal arteries or as athero-
embolism.
Ischemic nephropathy
Ten years have now passed since Jacobson’s study de-
fined ischemic nephropathy, raising a subject of nephro-
logical interest [14]. There are several causes of ischemic
nephropathy, but the most common is an atherosclerotic
process with which the name has become synonymous.
In his study, Jacobson analyzed the following: (1) the
history of atherosclerotic RVD; (2) patients at risk who
should be studied; (3) how they should be studied; and (4)
which treatment was the best. Later revisions have dealt
with this subject [15–17].
A significant renal artery stenosis (RAS)–60 to 75%
reduction in lumen size–must be confirmed by arteriogra-
phy, a technique that is not devoid of special risks in this
group due to the nephrotoxicity associated with iodinated
contrast media and to atheroembolism, and therefore it is
not indicated for large population studies.
The atheroma plaque is the main cause of RAS, and in
90% of cases there is evidence of atheromatous vascular
effects in other areas (supra-aortic, lower limbs and above
all coronary).
The prevalence found depends on the indication for the
study.
1. Studies based on autopsies. They confirm a greater
prevalence in elderly patients.
In non-selected material, a RAS . 50% was found in 5%
of patients under 64 years, as compared to 18% in those
between 65 and 74 years, and 42% in those over 75; there
was a severe bilateral stenosis in 50% of cases [18].
In another study using the same criteria in which the
mean age of patients was 61 years, severe RAS was
Table 1. Features supporting a diagnosis of hypertensive
nephrosclerosis
Black race
Family history: onset of hypertension between 25 and 45 years of age
Long-standing or severe hypertension
Evidence of hypertensive retinopathy
Evidence of hypertensive left ventricular hypertrophy
Onset of hypertension prior to the development of proteinuria
Absence of any other cause of primary renal disease
Biopsy evidence
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demonstrated in 17% of normotensive patients as com-
pared to 56% of hypertensive patients, with a 62% inci-
dence in patients over 70 years [19]. None of these studies
evaluated renal function.
2. Studies based on arteriography. These confirm the
above data. In Eyler et al’s study on 500 patients over the
age of 60, a critical RAS was found in 45% of normotensive
subjects, as compared to 76% of hypertensive patients [20].
Significant results from other studies include the follow-
ing: RAS . 50% in 38% of patients with aortic aneurysm,
33% of patients with aortic occlusive disease and from 39 to
45% of patients with occlusive disease of the lower limbs
[21].
3. Studies on patients on dialysis. Various studies have
assessed prevalence in recent years, usually on patients over
50 years of age. Diagnostic criteria were diverse: angiogra-
phy [22] or renal duplex sonography [23]. The results of
these confirm a prevalence of RAS ranging from 10 to 20%,
although in many cases a relationship between RAS and
renal failure could not be exactly defined. Confirmation
would come from recovery of renal function after therapy.
In some series, revascularization allowed for discontinua-
tion of dialysis in 80% of the cases, with dialysis being
started again within the first year in two of the patients
(10%) [24]. These results suggest a causal relationship
between RVD and ESRD, especially in patients with
bilateral disease.
Natural history
The natural history of vascular atheromatous disease
remains a controversial subject.
Progression of RAS detected by arteriography [25, 26] or
duplex sonography [27] was documented in almost half of
317 patients in six studies after a mean follow-up of
between six months and 15 years [25, 26].
A marked variability of between 1.5% to 5% per year has
been reported, regardless of hypertension control. Progres-
sion to complete occlusion was observed in approximately
15% of cases, usually occurring rapidly and arising earlier
the more severe the stenosis [25, 26].
In studies using duplex-scanning, progression to com-
plete occlusion was only seen in arteries with more than
60% luminal occlusion at the time of first evaluation, the
cumulative incidence of occlusion being 5% at one year and
11% at two years [27].
Once ESRD has been established, these patients repre-
sent a high risk group, with significant cardiovascular
co-morbidity factors. Mortality is high despite dialysis
treatment, and cardiovascular and cerebrovascular causes
are responsible for a mortality greater than 50% at three
years.
Diagnosis
Early diagnosis of RAS before occlusion is a clinical
challenge. Very few of the clinical signs and non-invasive
tests clearly identify these patients or indicate progression
towards occlusion in a known stenosis [28].
The diagnostic criteria of RAS are no different from
those for younger patients, but in elderly patients with
suspected RAS, diagnostic and therapeutic measures
should always be individualized, and take into account both
the expectation for possible renal function recovery and the
associated atherosclerotic disease, which can aggravate the
morbidity of interventional procedures.
There should be a high index of clinical suspicion in this
population, especially in older patients who show a pro-
gressive ESRD with no remarkable urinary sediment find-
ings, a proteinuria , 1 g/day, hypertension and clinical or
radiological atherosclerosis in several extrarenal sites (Ta-
ble 2).
This suspicion is also in order with excessive hyperten-
sion control upon the introduction of an angiotensin-
converting enzyme inhibitor (ACEI), and above all if an
acute impairment in renal function (normally reversible
upon drug discontinuation [14–16]) is observed, and when
repeated episodes of acute pulmonary edema occur in
elderly patients with preserved cardiac ejection fraction
[14].
In the presence of hypertension, the classical diagnostic
criteria of renovascular hypertension are valid. Ischemic
nephropathy should be suspected if there is progressive
uremia.
A definitive diagnosis requires good conventional arte-
riography with digital subtraction or the use of CO2 as the
contrast. In cases of high suspicion, direct performance
without any prior studies has been suggested. However, this
technique requires selective arterial catheterization, which
cannot detect stenosis at the ostium level and also carries
the risk of releasing an atheroembolism, especially in this
particular group.
ATHEROEMBOLISM
This is an underestimated condition caused by the spon-
taneous or traumatic release of fragments from atheroma
plaques and their introduction into the peripheral circula-
tion. The significant renal blood flow makes the kidney one
of the target organs, and mid-sized arteries generally
between 150 and 200 microns in diameter, such as the
Table 2. Features supporting a diagnosis of atheromatous renal
vascular disease
Age over 50 years.
Progressive renal failure associated with:
inactive urine sediment.
proteinuria under 1 g/day.
hypertension.
peripheral vascular disease.
vascular surgery or manipulation.
Angiographic evidence (ischemic nephropathy)
Biopsy evidence (atheroembolism)
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arquate and interlobar arteries, are occluded by such
emboli.
Renal atheroembolism may occur acutely as a complica-
tion usually following manipulation of atheromatous ves-
sels, or chronically, either are as a silent problem that
evolves to renal failure, or more commonly as a systemic
process with renal failure similar to a vasculitis. It is rare in
patients under 50, and most common in males over 60 years
who have extensive atheromatous disease. Its frequency
increases as the age of patients who undergo more invasive
treatments also increases.
According to the literature on this subject [29–31],
atheroembolism usually affects elderly men with, among
other factors, a prior history of hypertension, atherosclero-
sis or previous renal failure. In 14% of the cases there was
no predisposing factor [29].
Although it may arise spontaneously, atheroembolism is
usually secondary to vascular surgery (aortic, coronary or
carotid), invasive procedures involving arterial puncture
(especially those performed by a femoral route), or exces-
sive anticoagulation, such as in the case of fibrinolytic
therapy in acute myocardial infarction [29].
Atheroembolism may have a nonspecific onset with
fever, loss of weight, and pain in the lower limbs, similar to
a systemic disease. In other cases it may occur as an
exacerbation of hypertension. There is sometimes evidence
of peripheral embolism, with symptoms that may be cata-
strophic, and with evidence of tissue necrosis.
The renal disorder is characterized by the association of
acute renal failure and hypertension. It often presents as a
rapid worsening of these two pre-existing symptoms. Di-
uresis may be preserved depending on the severity of the
renal component and the patient’s general condition. Slight
proteinuria or urinary sediment do not help [30, 31]. It may
occasionally occur as a rapidly progressive glomerulone-
phritis with glomerular necrosis and extracapillary prolifer-
ation [32].
Diagnosis
The identification of any recent vascular invasive proce-
dure or anticoagulant treatment should lead to a suspicion
of the disease, and histological confirmation should be
obtained. However, more rarely the clinical picture may be
less impressive (especially as seen in the spontaneous form)
and the progression similar to that of a vasculitis, so the
diagnosis may only be made at autopsy [29].
Laboratory results may also be unclear, inconsistent and
contribute to the confusion. There may be an increased
erythrocyte sedimentation rate, leukocytosis with absolute
or relative eosinophilia, and low complement levels, as well
as the possible presence of rheumatoid factors and antinu-
clear antibodies. It is not unusual to find an increase in
intracellular enzymes. Urine may show proteinuria some-
times in the nephrotic range, microhematuria, leukocyturia,
eosinophiluria and casts. Urea and plasma creatinine grad-
ually increase.
The extensive differential diagnosis emphasizes the need
for histological confirmation. Examination of the eye fun-
dus may reveal cholesterol crystals. If there is no surgical
specimen available for examination, a skin biopsy from the
lower limbs, subcutaneous tissue or muscle may be used. If
the examination is positive for cholesterol emboli, a renal
biopsy is not required. In a review of 129 cases in the
literature, 31% were diagnosed by renal biopsy, 21% by
muscular biopsy, 17% by skin biopsy, 9% by clinical criteria,
and 22% postmortem [33].
However, in one necropsy study of 173 patients diag-
nosed as having atheroembolism, this was the only diagnos-
tic method used in 153 [29]. Cholesterol emboli were found
in 954 sites (a mean of 3.4 per patient) involving 32
different tissues. The five most commonly affected by order
of frequency were: kidney (74.5%), spleen (55%), pancreas
(52%), gastrointestinal tract (31%) and adrenal glands
(20%). Combined skin and muscle involvement occurred in
only 4% of postmortem diagnoses, as compared to 51% of
the pre-mortem diagnoses, which means that most sites
remain undetected and undiagnosed.
In conclusion, RVD is a heterogeneous group of dis-
eases. This group should be studied exhaustively, not only
for epidemiological reasons, but also for prognosis and
therapy. Early detection and control of high blood pres-
sure, and accurate diagnosis and successful treatment of
ischemic nephropathy will decrease the incidence of this
disease.
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